ABEO

Abeona Therapeutics Inc.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Abeona Therapeutics Inc. (ABEO) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A); its weakest is Momentum (D+). The rating has held at C+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
A
Factor Score 4.3 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
D+
Factor Score 1.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.4
EV / EBITDA -0.4
Rev Growth YoY N/A
Gross Margin -3.5%
Price Return 3M -57.8%
Price Return 12M -42.6%
Catalyst Signal 0.00
Market Cap $160.3M
TTM Revenue $39.0M
Price / Sales 4.1
ROE -42.1%

Historical Factor Score Progression

Held C+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B- (3.0) A (4.3) C- (2.1) D+ (1.8) C+ (2.6) C+ (2.8)
2026-11-10 B- (3.0) A+ (4.6) C- (2.1) C- (1.9) C+ (2.6) C+ (2.8)
2026-11-03 B- (3.0) A+ (4.6) C- (2.1) C- (2.0) C+ (2.7) C+ (2.8)
2026-10-27 B- (3.0) A+ (4.5) C- (2.1) C (2.2) C+ (2.6) B- (2.9)
2026-10-20 B- (3.0) A+ (4.5) C- (2.1) C- (2.1) C+ (2.6) B- (2.9)
Page 1 of 4